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Abstract
Background: Acute asthma attack is a frequent condition in children. It is one of the most common reasons for
emergency department (ED) visit and hospitalization. Appropriate care is fundamental, considering both the high
prevalence of asthma in children, and its life-threatening risks.
Italian Society of Pediatrics recently issued a guideline on the management of acute asthma attack in children over
age 2, in ambulatory and emergency department settings.
Methods: The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was
adopted. A literature search was performed using the Cochrane Library and Medline/PubMed databases, retrieving
studies in English or Italian and including children over age 2 year.
Results: Inhaled ß2 agonists are the first line drugs for acute asthma attack in children. Ipratropium bromide should
be added in moderate/severe attacks. Early use of systemic steroids is associated with reduced risk of ED visits and
hospitalization. High doses of inhaled steroids should not replace systemic steroids. Aminophylline use should be
avoided in mild/moderate attacks. Weak evidence supports its use in life-threatening attacks. Epinephrine should
not be used in the treatment of acute asthma for its lower cost / benefit ratio, compared to β2 agonists. Intravenous
magnesium solphate could be used in children with severe attacks and/or forced expiratory volume1 (FEV1) lower than
60% predicted, unresponsive to initial inhaled therapy. Heliox could be administered in life-threatening attacks.
Leukotriene receptor antagonists are not recommended.
Conclusions: This Guideline is expected to be a useful resource in managing acute asthma attacks in children
over age 2.
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Background
Acute asthma attack is a frequent condition in children. It
is one of the most common reasons for emergency depart-
ment (ED) visits and hospitalization [1]. It can be triggered
by viral infections, atypical bacteria (i.e. Mycoplasma pneu-
moniae) infections, allergens and/or air pollutants, includ-
ing tobacco smoke, medications, physical exercise, and
stress and emotions [1]. Acute asthma attack can occur as
a first episode in undiagnosed children or in children with
a previous asthma diagnosis and an uncontrolled disease
despite therapy [2]. Indeed, despite advances in therapy,
asthma remains a disease that is not optimally controlled
in many children [2]. Asthma attacks can be particularly
recurrent or life-threatening and increasingly expensive in
unresponsive children [2].
The multidisciplinary ISP panel recently issued a new
guideline on the management of acute asthma attack in
children over age 2, in ambulatory and ED settings, using
the GRADE methodology [3]. The guideline aims to deliver
up to date scientific evidence and recommendations to
pediatricians, general practitioners, Emergency Medicine
Physicians, and nurses.
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Methods
This Guideline was issued by the ISP, jointly with the
Italian Society of Pediatric Respiratory Diseases, the
Italian Society of Pediatric Immunology and Allergology,
and the Italian Society of Pediatric Emergency Medicine.
The document was developed by a multidisciplinary
panel of clinicians and experts in evidence-based medi-
cine who were identified with the help of the participat-
ing scientific societies. Specifically, the panel included
experts in the fields of general pediatrics, emergency
medicine, epidemiology, nursing practice, pharmacology,
research methodology, and a member of the parents’
association FEDERASMA. No panel member declared
any conflict of interest.
The panel met in two occasions, and many of the con-
sultations involved in the guideline development and
draft processes took place interactively by e-mail or
phone. The panel members first defined the objectives
of the guideline, the essential clinical questions, and the
appropriate inclusion and exclusion criteria for the stud-
ies from which evidence would be derived. They also
identified the information sources and biomedical data-
bases that would be consulted, and the search terms that
would be used in constructing the search strategy.
The objective of the guideline was to optimize the
management of acute asthma attack in children over age
2, in ambulatory and emergency department settings.
This guideline was not intended for children aged 2 years
or younger, with acquired or congenital immunodefi-
ciency, major pre-existing, chronic heart or lung disease,
and should not be used to treat children admitted to
hospital ward or to intensive care unit (ICU).
The quality of evidence and strength of recommenda-
tions were rated using the Grading of Recommendation
Assessment, Development, and Evaluation (GRADE)
approach [3].
Literature search
Literature search was performed using the Cochrane
Library and Medline/PubMed databases, using appropri-
ated key words and retrieving studies published between
January 2009 and December 2016, including children
aged more than 2 years. The results of this search were
then evaluated and selected based on both methodology
and relevance. An updated literature search was per-
formed before preparing the final draft; this search iden-
tified no additional relevant publications.
Study selection, levels of evidence, and strength of
recommendations
The selection of studies, data extraction and quality assess-
ment were performed by specially trained personnel, fol-
lowing the GRADE methodology [3]. Briefly, evidence was
evaluated according to six categories: 1) risk of bias, 2)
inconsistency, 3) indirectness, 4) imprecision, 5) publica-
tion bias, and 6) other criteria. Quality of the studies can
be up- or down-graded due to magnitude factors, limita-
tions in any of the aforementioned categories or other
factors [3]. Finally, 4 levels of quality of evidence were indi-
cated (high, moderate, low, very low). Subsequently, bal-
ances were assessed between benefit and harm, patients’
values and preferences, cost and resources, and feasibility
and acceptability of the intervention, and recommenda-
tions were formulated considering 4 grades of strength
(Positive-strong; Positive-weak; Negative -strong; Negative-
weak) [3]. A strong recommendation was worded as “we
recommend” or “it should…” and a weak recommendation
as “we suggest” or “it could…” The full text of the guide-
lines and all the related documents are available at the
website of the ISP (www.sip.it).
Results
Clinical and objective assessment
History should be collected very carefully since it is an
extremely important tool to predict the severity of exac-
erbations and the risk for hospitalization. Symptoms are
poorly related to the severity of airway obstruction.
Therefore, objective evaluations (i.e. pulse oximetry;
peak expiratory flow; FEV1; blood gas measurement)
should be considered [4–14]. However, the value of
pulmonary function parameters in the assessment of
patients with respiratory distress is modest [4–15]. Only
three high quality studies are available [11–13]. One is a
systematic review of 60 studies showing that none of the
available score are validated in the clinical practice [11].
The other one is an observational prospective study
including 101 children, aged > 6 years, demonstrating
that the Clinical Asthma Score was not related to the
spirometry results [12]. More recently Eggink and col-
laborators performed a prospective, high quality study,
reviewed and validated clinical scores for dyspnoea severity
in children, and authors concluded that the commonly used
dyspnoea scores have insufficient validity and reliability to
allow for clinical use without caution [13].
Levels of severity of the acute asthma attack and indica-
tions for hospitalization are summarized in Tables 1 and 2.
It should be underlined considering that low oxygen
saturation, especially after initial bronchodilator treatment,
allows the identification of patients with more severe
asthma [2, 16, 17]. Respiratory physiology studies showed
that in mild acute asthma attack, PaCO2 values are usually
normal. Increasing values of PaCO2 may be an ominous
sign of impending respiratory failure, in presence of respira-
tory distress [2, 16, 17].
Recommendation
Level of severity should be assessed considering both clin-
ical and objective evaluations, including pulse oximetry,
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Table 1 Management of acute asthma attack in children
Note. PEF is expressed as percentage of personal best. Not all parameters have to be abnormal, but a single abnormality may be sufficient to classify a patient
into a severity class. The severity category may change when more information is available or over time
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peak expiratory flow or FEV1. Blood gas measurement
should be reserved only to more severe attacks.
Positive strong recommendation
Treatments
Oxygen Numerous studies have confirmed that hyp-
oxia is almost always present during acute asthma
attack, its degree depending on the severity of the
episode [2, 14–17]. Therefore monitoring the blood
oxygenation level, mainly through pulse oxymetry, is
fundamental in order to select children who deserve
oxygen therapy. Oxygen saturation should be obtained
when the patient is breathing room air. However, it is
not necessary to cease oxygen therapy to measure pulse
oximetry, if it has already been started. Clinical judg-
ment should be applied in any circumstance [2, 16, 17].
Recommendation
Humidified oxygen therapy using a tight fitting face
mask or nasal cannula should be administered to
children with severe acute asthma attack and/or SpO2
< 92%. Flow rates and oxygen concentration may be
released by specific Venturi mask and should be suffi-
cient to achieve saturations of ≥ 95%.
Positive strong recommendation
Inhaled short-acting ß2 agonists
Inhaled short-acting ß2 agonists are the first line treatment
for acute asthma attack in children. Salbutamol is a useful
medication that can be used in children of all ages. Inhaled
via is the traditional route of administration [18]. Salbuta-
mol given continuously via nebulizer was not associated
with a better outcome with respect to frequent intermittent
administration, in a systematic review, dating back to 2003
and including only one pediatric study [19, 20]. In 2013
Cochrane including 1897 children and 729 adults in 39
trials, Metered-Dose Inhalers (MDI) with spacer was con-
sidered the preferred option for delivering ß2 agonists in
children with mild to moderate asthma attack [21].
Salbutamol dose to be administered through MDI with
spacer should be individualized according to the asthma
attack severity: 200–400 μg/dose (2–4 puffs/dose) could be
sufficient in mild attacks. Children with severe asthma
should receive frequent doses of nebulised bronchodilators
(2.5 to 5 mg of salbutamol), driven by oxygen, given the risk
of oxygen desaturation while using air-driven compressors.
Once improving on two- to four-hourly salbutamol, pa-
tients should be switched to a MDI with spacer [16, 17, 22].
Recommendation
Salbutamol is the first line treatment for acute asthma
attack in children. In severe attack it should be adminis-




MDI with spacer should be used to delivery ß2 ago-
nists in children with mild to moderate asthma attack.
Children with severe asthma should receive frequent
doses of nebulised bronchodilators (2.5 to 5 mg of sal-
butamol), driven by oxygen.
Positive strong recommendation
Intravenous short-acting ß2 agonists
Literature data regarding iv short-acting ß2 agonists use
are poor. No consistent evidence favoring the use of iv
short-acting ß2-agonists for patients with acute asthma
were evidenced in a 2012 Cochrane including 2 pediatric
studies on children (one in ICU) [23].
Some authors suggest the use of iv salbutamol in
addition of long-acting ß2 agonists in children with se-
vere asthma attack unresponsive to initial therapy [23].
The recommended dose is a single bolus of 15 μg/kg
(diluition: 200 μg/mL for central iv line; 10–20 μg/mL
for peripheral iv line) over 10 min, followed by continu-
ous infusion of 0.2 μg/kg /min. Higher doses (1–2 μg/
kg/min up to 5 μg/kg/min) can be administered in unre-
sponsive children [2, 16]. Intravenous salbutamol should
be given in the ICU with continuous ECG and twice
daily electrolyte and lactate monitoring [17].
Recommendation
Salbutamol could be administered intravenously (iv) in




Children receiving iv salbutamol should be admitted to
intensive care unit with continuous ECG and twice daily
electrolyte and lactate monitoring.
Positive strong recommendation
Ipratopium bromide
Ipratopium bromide induces a slower broncodilator re-
sponse than ß2 agonists, but the combination of the two
medications produces a synergic effect. In severe attack
Table 2 Conditions requiring hospitalization
Signs and symptoms of acute respiratory failure
Worsening of clinical parameters after bronchodilator treatment
SatO2 < 92% after bronchodilator treatment
PEF < 60% predicted after bronchodilator treatment
Concomitant complications (pneumothorax, atelectasies, pneumonia)
Severe asthma itself, irrespective of worsening;
History of previous severe life-threatening asthma episodes, or previous
admission to ICU
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the recommended nebulized dose is 125–250 μg/dose
(in children < 4 years of age) to 250–500 μg/dose (in
children ≥ 4 years of age), in combination with nebulized
salbutamol. It should be administered frequently, up to
3 times every 20–30 min, within the first hour. The
ipratropium dose should be tapered to 4 to 6 hourly or
discontinued [17]. Once ipratropium bromide is discon-
tinued, salbutamol dose should be tapered to one- to
two-hourly thereafter according to clinical response.
A 2012 Cochrane review [24] including four trials on
173 children found that treatment failure on anticholin-
ergics alone was more likely than when anticholinergics
were combined with short-acting ß2 agonists (OR 2.65;
95% CI 1.2 to 5.88). Authors concluded that inhaled
anticholinergic drugs alone are not appropriate for use
as a single agent in children with acute asthma exacerba-
tions. In a subsequent 2013 Cochrane review [25],
including 15 studies with 2497 children, the addition of
an anticholinergic to a SABA significantly reduced the
risk of hospitalization (RR: 0.73; 95% CI: 0.63 to 0.85).
Fewer children treated with anticholinergics plus short-
acting ß2 agonists reported nausea and tremors com-
pared to short-acting ß2 agonists alone; no significant
group difference was observed for vomiting. Authors
conclude that inhaled anticholinergics given in addition
to β2-agonists are effective in reducing hospitalizations
in children arriving in ED with a moderate to severe
asthma exacerbation [25]. Only one study yielded a dif-
ferent result, however it should be noticed that MDI
plus spacer was used [26]. It was a prospective, single-
blinded, randomized, controlled, equivalence trial in a
tertiary pediatric ED, including 347 children, and show-
ing that the addition of ipratropium bromide was not
significantly associated with a reduction in admission
rates [26]. In a 2014 Cochrane review, including 4 stud-
ies on 472 children admitted to pediatric wards, no
evidence of benefit for length of hospital stay nor other
markers of response to therapy was noted when neb-
ulised anticholinergics were added to short-acting
β2-agonists [27].
Recommendation
Nebulized inhaled ipratropium bromide, given in addition
to short-acting β2-agonists, should be administered in
children with a moderate to severe asthma attack.
Positive strong recommendation
Steroids
Systemic steroids (SS) have been reported to be effective
in the treatment of acute asthma attack in children, with
no difference between oral or intravenously/intramuscle
route of administration [28]. Therefore the oral steroids
are preferable, in the absence of vomiting. Dexametha-
sone, prednisone, and prednisolone are equally effective
even if dexamethasone is associated with a higher risk of
vomiting [28]. A recent open randomized trial [29] and
one meta-analysis including 6 pediatric studies [30]
demonstrated no different efficacy between prednisone
and dexamethasone in children with acute asthma
attack. However, this meta-analysis concludes that
“emergency physicians should consider single or 2-
dose dexamethasone regimens over 5-day prednisone/
prednisolone regimens for the treatment of acute
asthma exacerbations”, due to easier administration
and less side effects with dexamethasone [30]. A
recent meta-analysis including 18 studies with a total
of 2438 participants assessed the efficacy and safety of
any dose or duration of oral steroids versus any other
dose or duration of oral steroids for adults and chil-
dren with an asthma exacerbation [31]. Literature data
was not sufficient to discriminate whether shorter or
lower-dose regimens are less effective than longer or
higher-dose regimens, or indeed more adverse events
are associated with the latter. Thus, authors underline
that some regimen characteristics including palatabil-
ity, regimen duration, and costs should be considered
in order to improve adherence in individual patients
[31]. Another recent meta-analysis, including 10 RCT
in children, concluded that dexamethasone is likely to
have less adverse effects than others corticosteroids,
and similar efficacy in reducing hospitalizations and
revisits [32].
Considering the time needed to induce gene expres-
sion and protein synthesis, the majority of pharmaco-
logical effects of steroid are not immediate, but are
evident some hours after their intake. However, gluco-
corticoids can have rapid effects on inflammation which
are not mediated by changes in gene expression [33].
Therefore their efficacy is optimized by an early use.
Accordingly, an inverse association between time of
administration and risk of hospitalization has been
reported in a systematic review [34]. Steroid intake
within the first hour from admission to the ED was asso-
ciated with a significantly reduced time spent in the ED
and a lower hospitalization rate [33].
The optimal duration of steroid therapy is unclear,
some experts would suggest prolonging this therapy for
3 to 5 days, with no need to taper the dose at the end,
particularly using molecules with short or intermediate
half- life [34]. In a recent review acute single or recur-
rent systemic short-term (< 2 weeks) steroids in children
with asthma exacerbations did not show any concern
about short-term adverse effects [35].
However, it is important to underline the long-term
risks caused by recurrent administration of oral steroids
in children with asthma. Literature data report that chil-
dren who require more than four courses of oral cortico-
steroids as treatment for underlying disease, including
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asthma, are at increased risk of fracture [36]. Further-
more, the CAMP study demonstrated that multiple
oral corticosteroid bursts over a period of years can
produce a dose-dependent reduction in bone mineral
accretion and increased risk of osteopenia in children
with asthma [37].
Recommendations
Systemic steroids (SS) should be used in the moderate to
severe acute asthma attack in order to reduce the
hospitalization rate and the risk of recurrence. Oral




Six randomized controlled trials, overall including 1302
children, and 4 systematic reviews [38–47] were evidenced
through the literature search. Moreover other important
studies, although published before 2009, have been con-
sidered [48]. Higher clinical efficacy of inhaled high-dose
corticosteroids (ICS) with respect to the placebo was ob-
served in one randomized controlled trials (RCT) [38].
The addition of nebulized high-dose budesonide was eval-
uated in adjunction to standard therapy without oral
steroids in children with moderate-to-severe acute asthma
exacerbation [38]. Complete remission rate was signifi-
cantly higher (84.7% vs. 46.3%; P = 0.004) and need for
oral corticosteroids was significantly lower (16.9% vs. 46.
3%, P = 0.011) in the group receiving budesonide than in
control group [38].
Two RCTs, whose results have been reported in three
manuscripts [39–41], showed that addition of high
dose ICS to standard asthma attack therapy, including
SS, was not associated with clinical improvement after
one and 2 h. However, in one study, it was associated
with a decreased admission rate of children with severe
acute asthma [40].
Two randomized clinical trials compared the effective-
ness of high-dose of ICS vs, SS [42, 43], the results
showed that ICS and SS have the same efficacy to
improve clinical symptoms. However, one study [38]
showed that in the group treated with high doses of
budesonide (800 μg/ 20 min) there was an increase in
the percentage of children discharged from hospital after
2 h compared to the group treated with prednisolone
(2 mg/kg).
A systematic review including eight studies published
between 1995 and 2006 [44] showed no differences in
the treatment with high-dose ICS or SS regarding admis-
sion rates, ED visits and rescue medications.
Two Cochrane reviews [45, 46], including both adult
and pediatric studies, conclude that there is insufficient
evidence that ICS treatment results in clinically important
changes in pulmonary function or clinical scores when
used in acute asthma in addition to SS [45, 46]. Therefore
there is insufficient evidence that ICS therapy can be used
in place of SS therapy when treating acute asthma [45,
46]. A 2012 Cochrane Review [47] evaluated the effective-
ness of the ICS treatment after discharge from ED and
concluded that ICS provides no additional benefit to
standard therapy with SS in the post-discharge treatment
of children with acute asthma. In conclusion, there was
some evidence that high doses of ICS can be as effective
as SS in the post-discharge treatment of children with
acute asthma. However, it should be noticed that the set-
tings where the trials have been performed - including
specifically dedicated nurses and/or doctors - are difficult
to replicate in the everyday practice in ED or ambulatory.
In such situations, prudently, SS should be preferred. In
addition, higher cost of ICS should be considered.
Recommendation
– High doses of ICS should not be used instead of SS
in asthma attack.
Negative strong recommendation
– Children treated with ICS can continue to use the
usual doses of ICS during the asthma attack.
Positive strong recommendation
Aminophylline
Several studies are available comparing the efficacy of
aminophylline in different clinical settings (i.e. aminoph-
ylline compared to placebo when added to inhaled
β2-agonists, or compared to iv salbutamol in more
severe attacks) [49]. In a recent review results from 12
RCTs, involving 586 children, and comparing aminoph-
ylline with placebo or usual treatment were summarized
[49]. Improvement in clinical severity scores was found
in 3 RCTs but not confirmed in other six, while 2 RCTs
showed improved lung function scores and two did not
[49]. One trial showed that iv aminophylline reduced
ICU admission rates, but no trial evidenced any benefit
of aminophylline on length of hospital or ICU stay [49].
Seven out of these 12 trials have been included in a 2005
Cochrane review [50]. This review concluded that intra-
venous aminophylline improved lung function within
6 h of treatment, but did not appear to reduce symp-
toms or length of hospital stay, and there was insuffi-
cient evidence to evaluate its impact on ICU rates
[50]. In conclusion, in the setting of moderate asthma
attack, the association of aminophylline to inhaled β2
agonists and steroids in acute asthma does not offer
substantial benefits [49, 50].
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In the setting of severe asthma attacks data of the
literature comparing iv salbutamol with iv aminophylline
are poor [49, 51], and no substantial difference of effi-
cacy emerges between the two drugs. In particular, iv
aminophylline and salbutamol (or terbutaline) have been
compared, head-to-head, in 4 RCTs including 202 chil-
dren [49]. In three trials no different clinical severity
scores were reported between iv salbutamol and iv ami-
nophylline. Moreover no difference was observed in the
one study reporting ICU admission rates and in two
RCTs reporting length of hospital stay [49]. No study
reported lung function outcomes. These paediatric stud-
ies have been included in a subgroup analysis in a
Cochrane review [51], concluding that there was no con-
sistent evidence to help decide between iv aminophylline
and iv salbutamol as therapy of choice. In a recent study,
a single i.v. dose of magnesium sulphate, added to in-
haled β2 agonist and SS, was more useful and safe than
iv aminophylline in 100 children with severe acute
asthma [52]. In summary, the administration of iv ami-
nophylline can be considered in addition to usual care in
patients with impending respiratory failure and in those
who have shown a good response to the drug in the
past [2, 16, 17]. Serum levels measurements are needed,
especially in patients already being treated with oral
aminophylline [2, 16, 17]. Few studies are available
regarding the use of low dose of aminophylline but
further data are needed regarding this issue [53].
Recommendation




Iv Salbutamol or iv aminophylline could be used in se-
vere acute asthma in children non-responder to inhaled
β2 agonist and oral corticosteroids. There are no signifi-
cant differences between the two treatments.
Positive weak recommendation
Epinephrine
Epinephrine does not offer any advantages compared to
β2 agonist in the treatment of acute asthma and is asso-
ciated with a greater risk of side effects, especially in
hypoxemic patients. Epinephrine could be used if β2ago-
nists are not available [2, 16, 17].
Recommendation
Epinephrine should not be used in the treatment of




The childhood experiences are still limited and related
to the use of a single dose of 25–40 mg/kg iv. In a recent
RCT of moderate quality [54] in 143 children with
severe asthma, the intravenous administration of magne-
sium sulphate during the first hour was associated to a
significant decrease in the number of patients who re-
quired mechanical ventilation. In a pharmacokinetic
study [55] in 19 children with severe asthma, a bolus of
magnesium sulphate (50–75 mg/kg), followed by con-
tinuous infusion (40 mg/kg/h) for 4 h, was safe and
maintained appropriated levels of Mg in serum.
There are conflicting data about the use of nebu-
lized MgSO4 in addition to β2 agonists in asthma
exacerbations [56, 57].
One RCT that included 508 children with severe acute
asthma [58] compared the effect of nebulized magnesium
sulphate to placebo. In the treated group there was a
statistically significant improvement in asthma score after
60 and 240 min. However, the clinical relevance of this
finding is uncertain. No serious adverse event was ob-
served in 19% of patients in the Mg group and in 20% of
the controls. Moreover, the study concludes there might
be a role for nebulised MgSO4 in children with a severe
exacerbation whose SaO2 in air after the first nebulised
treatment remains below 92%, and in those with a shorter
duration of symptoms [58]. Similarly a role of nebulised
MgSO4 has been considered by other authors [59], but
further studies are needed at this regard.
A recent RCT evaluated the effect of nebulized MgSO4,
on FEV1 and PEF in children with asthma induced by
acetylcholine [60]. The nebulized MgSO4 showed a wide
bronchodilator effect but the rise in FEV1 and PEF was
not superior to salbutamol. There is no evidence to
support that the combination of salbutamol and magne-
sium sulphate displays a synergistic effect. No significant
adverse event risk was reported.
A recent meta-analysis [61] including 5 studies (182
children) demonstrated that treatment with iv MgSO4
reduced the odds of admission to hospital by 68%.
Adverse events have not been reported consistently with
magnesium sulphate therapy.
Recommendation
MgSO4 could be used intravenously in children with
severe asthma not responding to the initial treatment.
MgSO4 could be also used if FEV1 is less than 60% pre-
dicted, after the first hour.
Positive weak recommendation
Recommendation
Nebulized MgSO4 should not be used in mild, moderate
or severe asthma, since the available evidence is poor.
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Negative strong recommendation
Heliox
A gas mixture containing helium / oxygen (Heliox) can
decrease respiratory failure and improve ventilation in
patients with airway obstruction. The use of this mixture
is not indicated in mild-moderate asthma. It can be used
as an alternative to oxygen in severe asthma not
responding to the initial treatment [62].
According to results of a systematic review of 5
pediatric RCT (1996–2010) and 143 children, there are
insufficient data to support the routine use of heliox in
acute asthma. In particular, not benefits in terms of rate/
length of hospitalization, nor percentage of children
requiring intubation have been demonstrated [63]. How-
ever, it is a safe therapy, and some data suggest that it
may be beneficial to patients with severely impaired lung
function. A systematic review and meta-analysis [64], in-
cluding 3 pediatric studies and 113 children, showed that
heliox used as a vehicle to deliver β2 agonist (compared
to oxygen) was associated with improvement of acute
asthma, especially in most severe attacks. It also was as-
sociated with reduced need for hospitalization [64].
Notably, to administer the heliox, a non-rebreathing
high-flow system is needed. Heliox needs a high flow of
oxygen to the appropriate sized particles.
Recommendation
A helium-oxygen mixture (70%: 30%) could be used in
severe asthma unresponsive to standard therapy.
Positive weak recommendation
Leukotriene modifiers
A Cochrane review was available including 1470 adults
and 470 children (aged 2–12), treated for acute asthma in
ED and randomized to receive montelukast or placebo in
addition to standard therapy [65]. No statistically signifi-
cant difference was found in the risk of hospitalization
with the use of oral montelukast in addition to standard
therapy [65]. These results have been recently confirmed
by Wang and colleagues in one trial comparing montelu-
kast versus placebo in 117 children, aged 2 to 5 years,
demonstrating no difference in PEF and lung function im-
provement [66].
Recommendation
Leukotriene modifiers in addition to standard therapy
should not be used.
Negative strong recommendation
Conclusions
This guideline is an updated tool for the management of
acute asthma attack in children over age 2. The review
of the literature supports the use of salbutamol as the
most appropriate β2 agonist. Adding ipratropium brom-
ide is an effective aid in moderate and severe attack.
Oral corticosteroids should be used in moderate-to-
severe acute asthma attacks to prevent hospitalizations
and symptom relapse. Adding steroids to the moderate
and severe attacks is more effective if administered at an
early stage. Intravenous steroids should be reserved for
selected children who are unable to take oral medica-
tions. High doses of inhaled steroids should not replace
systemic steroids. Aminophylline use is not recom-
mended in mild to moderate acute asthma attacks.
Weak evidence supports its use in life-threatening at-
tacks.Epinephrine should not be used in the treatment
of acute asthma for its lower cost / benefit ratio, com-
pared to β2 agonists. The use of iv MgSO4 could be con-
sidered only in children with severe asthma attack who
are unresponsive to initial treatment and/or who have
FEV1 less than 60% predicted, after 1 h of standard ther-
apy. Helium-oxygen mixture (70%:30%) can be used in
severe asthma attack unresponsive to standard therapy.
Leukotriene modifiers are not currently recommended.
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